Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Temraz
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors S. Temraz1, W. Albonji2, M. Charafeddine2, Z. Farhat2, D. Mukherji1, A. Shamseddine1
  • 1American University of Beirut Medical Center, Beirut, Lebanon, /
  • 2AUB, Beirut, Lebanon, /

Abstract

Neo-adjuvant therapy with FOLFIRINOX in patients with locally advanced/borderline resectable pancreatic cancer has the potential to down-stage tumors enabling surgical resection. The aim of this study was to evaluate the effect of neo-adjuvant FOLFIRINOX and determine the proportion of patients who proceeded to surgery (resulting in R0 or R1 resection) following FOLFIRINOX induction therapy. Secondary objectives included response rate to FOLFIRINOX therapy (Complete Response (CR)/Partial Response (PR)/stable disease (SD)), assessing the toxicity and calculating Progression Free Survival (PFS) and Overall Survival (OS).